Zontivity(vorapaxar)
Zontivity (vorapaxar) is a small molecule pharmaceutical. Vorapaxar was first approved as Zontivity on 2014-05-08. It is used to treat coronary disease, myocardial infarction, and peripheral arterial disease in the USA. It has been approved in Europe to treat myocardial infarction. The pharmaceutical is active against proteinase-activated receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vorapaxar sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZONTIVITY | Key Therapeutics | N-204886 DISCN | 2014-05-08 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zontivity | New Drug Application | 2022-10-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| coronary disease | — | D003327 | — |
| peripheral arterial disease | EFO_0004265 | D058729 | — |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 3 | 3 | — | 7 |
| Infarction | D007238 | EFO_0009463 | — | — | 1 | 3 | 1 | — | 5 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 1 | 2 | — | 3 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | 1 | 1 | — | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | 1 | 3 | — | — | 4 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | 3 | — | — | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 1 | — | — | 2 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 1 | — | 1 | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral infarction | D002544 | — | I63 | — | 1 | — | — | — | 1 |
| Arteriovenous fistula | D001164 | — | Q27.3 | — | 1 | — | — | — | 1 |
| Fistula | D005402 | — | — | — | 1 | — | — | — | 1 |
| Hiv | D006678 | — | O98.7 | 1 | 1 | — | — | — | 1 |
| Coronary disease | D003327 | — | — | — | 1 | — | — | — | 1 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vorapaxar |
| INN | vorapaxar |
| Description | Vorapaxar is a carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation. It has a role as a protease-activated receptor-1 antagonist, a platelet aggregation inhibitor and a cardiovascular drug. It is a member of pyridines, a carbamate ester, an organofluorine compound, a naphthofuran and a lactone. It is a conjugate base of a vorapaxar(1+). |
| Classification | Small molecule |
| Drug class | Protease-activated receptor 1 (PAR1) antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 618385-01-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL493982 |
| ChEBI ID | 82702 |
| PubChem CID | 10077130 |
| DrugBank | — |
| UNII ID | ZCE93644N2 (ChemIDplus, GSRS) |
Target
Agency Approved
F2R
F2R
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,229 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zontivity
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
189 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use